A
10.26
0.55 (5.66%)
| Previous Close | 9.71 |
| Open | 9.80 |
| Volume | 1,087,150 |
| Avg. Volume (3M) | 477,501 |
| Market Cap | 416,627,840 |
| Price / Earnings (Forward) | 96.15 |
| Price / Sales | 1.47 |
| Price / Book | 2.23 |
| 52 Weeks Range | |
| Earnings Date | 14 Jul 2025 - 18 Jul 2025 |
| Profit Margin | -14.61% |
| Operating Margin (TTM) | -9.23% |
| Diluted EPS (TTM) | -1.01 |
| Quarterly Revenue Growth (YOY) | -4.20% |
| Total Debt/Equity (MRQ) | 5.76% |
| Current Ratio (MRQ) | 2.21 |
| Operating Cash Flow (TTM) | -23.94 M |
| Levered Free Cash Flow (TTM) | -7.38 M |
| Return on Assets (TTM) | -6.55% |
| Return on Equity (TTM) | -20.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | AngioDynamics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.9
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.5 |
| Average | 1.88 |
|
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 5.60% |
| % Held by Institutions | 90.63% |
| 52 Weeks Range | ||
| Median | 16.00 (55.95%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Apr 2025 | 16.00 (55.95%) | Buy | 9.31 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Jun 2025 | Announcement | AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F18⁸⁵ System for Treatment of Acute Pulmonary Embolism |
| 02 Apr 2025 | Announcement | AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |